Bayer Healthcare's Arctic Wonder Market Test Succeeds With Neptune Krill Oil Leading to U.S. National Launch
09 April 2011 - 1:13AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) is pleased to announce that Bayer
Healthcare, LLC Consumer Care Division has formally launched its
Arctic Wonder proprietary Neptune Krill Oil ("NKO") in the United
States in March 2011 after a successful market test.
Bayer's market test conducted over the last year with NKO® under
its Arctic Wonder brand was performed in the U.S. internet direct
response e-commerce channel of trade.
"Acasti management team is delighted by the relationship Neptune
has developed with Bayer. This is yet another significant milestone
for Neptune's strategic planning which will help NKO® achieve
extensive consumer awareness and appreciation. We are looking
forward to a successful long-term collaboration with Bayer," stated
Dr. Tina Sampalis, President of Acasti Pharma.
"The agreement with Bayer, the market test results and the
marketing approach for Arctic Wonder NKO® not only create broad
consumer awareness, confidence and appreciation but also
distinguish NKO® as the superior and prime choice amongst
competitor krill oil products," said Mr. Henri Harland, President
and CEO of Neptune. "Arctic Wonder is entering the rapidly growing
omega-3 market which has shown a sustained annual growth of 12%
according to the Frost and Sullivan Report 2010. The omega-3
category is valued at $1.7 billion and expected to reach $3.5
billion in 2015. We believe the full launch by Bayer of Arctic
Wonder will achieve immediate success which will in turn positively
influence our growth and increase Neptune's krill oil market share,
reinforcing Neptune's position as the industry leader and Neptune
Krill Oil as the gold standard of quality and efficacy for krill
oil products in the market," he added.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
Acasti is in the process of listing its common shares on the TSX
Venture Exchange.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024